Articles tagged with “fda-regulatory-status”

Deramiocel for DMD: HOPE-3 Cell Therapy Trial Outcomes

Analyze the HOPE-3 Phase 3 trial results for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy. Review PUL v2.0 data and FDA status.

35 min read

4/28/2026

deramiocel duchenne muscular dystrophy dmd cell therapy hope-3 trial capricor therapeutics pul v2.0 dmd cardiomyopathy fda regulatory status